Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases
Clinical Trials · 2026
DOI: 10.1177/17407745251387571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, 2026. Verfasst von Christine Girges und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Movement Neurosciences, Institute of Neurology, University College London, London, UK. Hauptthemen laut MEDLINE: Depression, Parkinson Disease, Patient Reported Outcome Measures, Multiple System Atrophy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defeat MSA, Van Andel Institute, cure parkinson's trust.
Themen: Depression
Abstract (Originalsprache)
Introduction
Depression can be an intrinsic part of neurodegeneration, or a reaction to the onset of motor or non-motor disability. Depression can also adversely influence an individual’s perception of their disease, independently of its severity or impact on function. Participant-reported outcome measures are recognised as an important adjunct to objective clinical trial data. Although severe depression is a frequent contraindication for trial participation, mild-to-moderate depressive symptoms could potentially influence the outcome of such questionnaires. We aimed to explore this within two interventional trials for Parkinson’s disease (Exenatide PD3; NCT04232969) and multiple system atrophy (Exenatide MSA; NCT04431713).
Methods
Prior to investigational drug exposure, participants completed either the Patient Health Questionnaire or Beck Depression Inventory-II, which allowed us to dichotomise them into two groups (normal or mild-to-moderately elevated burden of depressive symptoms). Participants with Parkinson’s self-completed the Movement Disorder Society Sponsored Revision of the Unified Parkinson’s disease Rating Scale Parts 1b and 2, Parkinson’s Disease Questionnaire-39, Non-motor Symptoms Scale and EQ-5D-5L, while participants with multiple system atrophy self-completed a Quality of Life scale and had assistance with completing the Unified Multiple System Atrophy Rating Scale Part 1. The Movement Disorder Society Sponsored Revision of the Unified Parkinson’s Disease Rating Scale Part 3 and Unified Multiple System Atrophy Rating Scale Part 2 provided objective, clinician-rated measures of motor severity.
Results
A mild-to-moderately elevated burden of depressive symptoms was identified in 32.5% (63/194) and 42.0% (21/50) of Parkinson’s and multiple system atrophy participants, respectively. Despite the normal and elevated groups being comparable in terms of disease duration and objective motor severity, those with a mild-to-moderately elevated burden of depressive symptoms self-reported worse disease impact. However, measures which involved clinician and/or carer input (Unified Multiple System Atrophy Rating Scale Part 1) were not influenced by co-existing depressive symptoms.
Conclusions
Mild-to-moderate depressive symptoms, below the threshold for diagnosing a depressive disorder, are associated with negative self-reporting, and such findings should be carefully considered when planning the design and analysis of trials in neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Movement Neurosciences, Institute of Neurology, University College London, London, UK.
- Clinical Research Centre for Movement Disorders and Gait, Kingston Centre, Parkinson's Foundation Centre of Excellence, Monash Health, Cheltenham, VIC, Australia.
- Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
- The Comprehensive Clinical Trials Unit, University College London, London, UK.
- Department of Statistical Science, University College London, London, UK.
- The Francis Crick Institute, London, UK.
ORCID-Profile: Christine Girges
Förderung
- Defeat MSA
- Van Andel Institute
- cure parkinson's trust
- John Black Charitable Foundation
- Efficacy and Mechanism Evaluation Programme
Zitieren
APA
Girges, C., Vijiaratnam, N., King, A., Auld, G., McComish, R., Chowdhury, K., Ambler, G., Maclagan, K., Limousin, P., Athauda, D., Morris, H. R., Libri, V., Foltynie, T., & Exenatide PD3 and MSA Trials Consortia (2026). Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases. Clinical Trials. https://doi.org/10.1177/17407745251387571
Vancouver
Girges C, Vijiaratnam N, King A, Auld G, McComish R, Chowdhury K, et al. Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases. Clinical Trials. 2026. doi:10.1177/17407745251387571
BibTeX
@article{Girges2026,
author = {Girges, Christine and Vijiaratnam, Nirosen and King, Alexa and Auld, Grace and McComish, Rachel and Chowdhury, Kashfia and Ambler, Gareth and Maclagan, Kate and Limousin, Patricia and Athauda, Dilan and Morris, Huw R and Libri, Vincenzo and Foltynie, Thomas and Exenatide PD3 and MSA Trials Consortia, Exenatide PD3 and MSA Trials Consortia},
title = {Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases},
journal = {Clinical Trials},
year = {2026},
doi = {10.1177/17407745251387571}
}
EUVIMED